Sheena Dempsey

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

5

[Article] KOL Engagement Dynamics - Influence Levels by Phase In this part 1 of 3 on "Navigating KOL Engagement Dynamics", we present our first key insight from our KOL engagement strategy report. This article addresses how pharmaceutical companies engage with KOLs possessing specific levels of influence to support the activities of the pharmaceutical organization during particular times within a product development lifecycle. Read on here: https://lnkd.in/eWbfURSs #medicalaffairs #msl #msls #thoughtleader #pharmaceuticalindustry #healthcare

5

Meetings between pharma and managed care organizations are increasingly more focused on financial topics than clinical ones. https://ow.ly/WiaC50SmHWS MMIT’s Jonathan Cecire and Norstella's Dinesh Kannan Kabaleeswaran discuss what manufacturers can do to ensure their brand messaging resonates with payers. #PharmaIndustry #ManagedCare #PharmaMarketing

9

Connecting the systems involved in the lifecycle management of clinical supplies closes the gap between the physical and digital supply chain, reducing the effort required to manage trial data and lowering overall risk. Having access to real-time, quality data enables sponsors to make timely and informed decisions. Read more today from Abby Sener, PMP, Almac One Manager at IXRS®3 by Almac Clinical Technologies in her latest feature in Applied Clinical Trials Magazine: https://hubs.li/Q02Q4mDl0

15

In the latest issue of IBI Journal, Sarah McAliskey from Almac Clinical Services shares invaluable insights on leveraging technology and expertise to protect clinical trial supply. Her expertise highlights the critical impact of these practices on the pharmaceutical industry. Don't miss her feature on pages 56-58! Read more here:https://hubs.li/Q031G_0N0

33

1 Comment

Advancements in #AI are helping experts leverage pharmacovigilance data to proactively identify links between clinical or environmental factors and adverse effects. Read this article from Oracle Life Sciences’ Bruce Palsulich for more: https://lnkd.in/dwCAiEmY

1

In a new guide, Pia Soeegaard Johansson Windeloev, VP of Life Sciences Strategy and Product Marketing at Lionbridge, outlines the three levels of language requirements a manufacturer or clinical trial sponsor must consider in order to ensure life sciences regulatory compliance under the EU Medical Device and Clinical Trial Regulations. https://brnw.ch/21wPdmc #ClinicalTrials #MedicalTranslation #LanguageServices #EUMDR

18

Why Summits is excited for our upcoming 23rd Pharma & BioTech PPM Conference being held in Boston, Ma (Oct. 16, 17, 18). Please contact me or Simona Marčeková to discuss attending or speaking at this event. #PPM #Pharma #Conference #ProjectManagement

5

#2025 holds exciting promises for the expanded use and integration of #RealWorldData in research and clinical trial projects. 🌿 In his latest article, Briya Co-founder and CEO David Lazerson shares his 5 Real-World Data Predictions for 2025—highlighting key trends and innovations set to shape the next 12 months. From AI-driven #LargeLanguageModels, to global data collaboration, discover how the future of real-world data is poised to revolutionize healthcare research. 📖 Read the full blog here https://lnkd.in/dw3g2Pn2

19

For over three decades, major Patient Blood Management (#PBM) associations, #pharmaceutical companies, #manufacturers, and #bloodless surgery hospital programs have heavily marketed to doctors, believing their buy-in was essential. However, this approach may have overlooked broader areas of interest. In the past five years, we've shifted our focus to cultivating public interest in Patient Blood Management, becoming pioneers in this approach. This has proven immensely valuable, creating an engaged infrastructure between healthcare providers and patients, enhancing understanding and collaboration in this evolving field of medicine. To address emerging challenges such as patient experience, safety, communication, and language, we're excited to introduce our Collaborative Optimal Outcome Language (COOL) initiative. This program provides support and training for hospitals to adapt to changing trends, paradigm shifts, and the needs of this new healthcare culture. The engagement bridge we've constructed is now open for all stakeholders in PBM to have open public access as we work together in collaboration, exchange, and education of a new language in life.

19

4 Comments

New Blog Post Alert! Our latest blog highlights how Prescient supported a mid-size, oncology-focused pharmaceutical company in transforming its evidence-generation capabilities. This post showcases how proactive, strategic planning can enable impactful evidence generation that drives real-world success. Read more: https://bit.ly/3YY7Tef #Biopharma #EvidenceGeneration #OrganizationalTransformation #Oncology

19

As we mark the first anniversary of the EMA’s Policy 0070 relaunch, it’s essential to evaluate its effects on clinical trial data sharing. Explore the key insights and ongoing challenges that may influence your compliance strategy. https://ow.ly/jTuV50TMzs2 #ClinicalTransparency #EMAPolicy0070 #ClinicalTrials #PharmaRegulations #DataProtection

13

Register now: https://loom.ly/V7hvN_g Join experts from AssistRx and MMIT (Managed Markets Insight & Technology) on Dec. 3 at 1 p.m. ET to discover the strategies life sciences organizations can use to alleviate copay program disruptions in 2025. During the webinar, we’ll detail how the perfect blend of tech and talent can help address recent payer activity, including new payer utilization management strategies and the changing copay accumulator and maximizer landscape. Can’t make it live? Request a recording when you sign up to view on your schedule. #InformedAccess #ImprovedOutcomes

15

Wilfred Mascarenhas, Executive Director of Eli Lilly and Company, joins fellow industry experts in hosting BioPhorum IT Digital and Data’s webinar on 10 December 15:00-16:30 GMT, where attendees will hear key highlights and recommendations from our publication ‘Managing data as a product for digital transformation in the pharmaceutical industry’.     You can register here: https://lnkd.in/e-gb5qKT     Wildred shares, “There is no one-size-fits-all when it comes to figuring out how to enable and resource building of the data products. At Lilly, we’ve used a hybrid approach. The definition, ownership and governance of the data products is done by the various business functions and process owners (data mesh approach), while the build of the data products, GMP validation, etc. is done centrally by IT (data fabric approach).”      #pharma #dataproducts

21

1 Comment

GI Partners has acquired a majority stake in eClinical Solutions, a key player in digital clinical software and services, to bolster its AI-powered data products and biometric services. This strategic move cements eClinical’s status as a trusted ally for pharmaceutical firms navigating complex trials and driving research advancements. Established in 2012, eClinical has been at the forefront of addressing clinical data challenges. Its elluminate Clinical Data Cloud® platform streamlines data processes, reduces cycle times, and boosts efficiency, positioning clinical trials for future success. Serving 16 of the top 50 biopharmaceutical companies, eClinical leverages its platform to unlock crucial data insights. Raj Indupuri, CEO of eClinical, underscores the company’s commitment to providing clients with a data and analytics infrastructure that expedites treatment delivery to patients. Bob Arnesen, President of eClinical, praises GI Partners’ expertise in scaling biopharmaceutical tech businesses and their market acumen, expecting the partnership to drive value for clients and partners. David Kreter, Managing Director at GI Partners, acknowledges eClinical's exceptional business and platform, emphasizing its role in facilitating informed decision-making and fostering biopharma innovation. GI Partners' investment will propel eClinical towards expanding its product offerings and enhancing its AI capabilities, ensuring cutting-edge clinical trials in the future. Read more: https://lnkd.in/dh28WYwJ Rachel Lowrey Christopher Dapolite Raj Indupuri

4

Using MMIT data, researchers found that Part D plans are more likely than employer-sponsored plans to prefer reference biologics to biosimilars. https://ow.ly/MGWi30sFTEf This will change with the full implementation of the IRA. Learn more in this Q&A with Harvard researcher Luca Maini.

5